Gyre Therapeutics, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $32.9 million (+0.7% year over year) and diluted EPS of -$0.04. It usually reports 36–71 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Mar 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–71 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
33
+0.7%
|
-2
-228.6%
|
-0.04
-500.0%
|
|
Aug 7, 2026
38 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
29
-2.1%
|
-14
-537.9%
|
-0.12
-300.0%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
23
+2.1%
|
-19
-476.2%
|
-0.10
|
|
Mar 12, 2026
71 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
24
-15.4%
|
-1
-320.7%
|
0.03
+2838.3%
|
|
Nov 7, 2025
38 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
33
+28.3%
|
2
-32.5%
|
0.01
+0.0%
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
30
+17.9%
|
-2
-149.3%
|
-0.03
-400.0%
|
|
May 9, 2025
39 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
22
-18.8%
|
5
-50.3%
|
0.00
-100.0%
|
|
Feb 18, 2025
49 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
28
|
1
+100.7%
|
-0.00
+100.0%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GYRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1124105
- Former names
- CATALYST BIOSCIENCES, INC. (until Oct 27, 2023); TARGACEPT INC (until Aug 19, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.